The global prostate cancer therapeutics market was valued at USD 14.55 billion in 2025 and is projected to reach USD 37.92 billion by 2035, advancing at a 10.06% CAGR from 2026 to 2035, according to SNS Insider. Growth is being supported by rising prostate cancer incidence, longer patient longevity, wider PSA and genomic testing, and greater use of personalized treatment. Hormonal therapy and androgen-receptor pathway inhibitors held about 40% of the market in 2025, while metastatic castration-resistant prostate cancer accounted for roughly 34% and oral medicines represented about 64%. North America led with approximately 45% of the market, while Asia Pacific is forecast to grow fastest at about 13.12% annually. Radioligand and radiopharmaceutical therapy, PARP inhibitors, PSMA-targeted imaging and therapy, combination regimens and artificial intelligence are key areas of development, although treatment costs and specialized infrastructure remain access constraints.